Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
Jacques P. Brown(Centre hospitalier de l'Université Laval), José Zanchetta(Universidad del Salvador), Ricardo E. Dent-Acosta(Amgen (United States)), Beiying Ding(Chinese University of Hong Kong), Javier San Martín(Universidad Nacional de Educación a Distancia), Andreas Grauer(Omeros Corporation (United States)), Rachel B. Wagman(Amgen (United States)), David W. Dempster(Columbia University)
Cited by 89
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k